1. Market Research
  2. > Ulcers - Pipeline Review, H2 2013

Ulcers - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 44 pages

Ulcers - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Ulcers - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcers. Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ulcers.
- A review of the Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ulcers pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ulcers pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Ulcers - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ulcers Overview 6
Therapeutics Development 7
Pipeline Products for Ulcers - Overview 7
Pipeline Products for Ulcers - Comparative Analysis 8
Ulcers - Therapeutics under Development by Companies 9
Ulcers - Therapeutics under Investigation by Universities/Institutes 11
Ulcers - Pipeline Products Glance 12
Early Stage Products 12
Ulcers - Products under Development by Companies 13
Ulcers - Products under Investigation by Universities/Institutes 14
Ulcers - Companies Involved in Therapeutics Development 15
Ahn-Gook Pharmaceutical Co., Ltd. 15
Angelini Group 16
Laboratorios Farmaceuticos Rovi, S.A. 17
TechnoPhage SA 18
Ulcers - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Assessment by Therapeutic Class 27
Drug Profiles 29
pantoprazole - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
TP-102 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
RO-17 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Compound 6a - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
New MCPs Inhibitors - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Acid Pump Antagonists - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Ulcers - Dormant Projects 35
Ulcers - Discontinued Products 36
Ulcers - Product Development Milestones 37
Featured News and Press Releases 37
Aug 29, 2013: Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Four Lots of Cubicin 500Mg in 10Ml Single Use Vials Due to Presence of Particulate Matter 37
Aug 06, 2013: Application Submission for Approval for the Stability-Improved Formulation of Limaprost, an Oral Prostaglandin E1 Analogue in Japan 37
Jun 13, 2013: Xoma Initiates Pilot Trial Studying Gevokizumab In Patients With Pyoderma Gangrenosum 37
Dec 20, 2012: Stroke Drug Kills Bacteria That Cause Ulcers And Tuberculosis, Study Finds 38
Dec 06, 2012: EU Court of Justice Upholds €52.5m Fine Against AstraZeneca Group 38
Oct 01, 2012: Horizon Pharma Announces Completion Of Sales Force Expansion 39
May 22, 2012: PLx Pharma Files New Drug Application For PL2200 Aspirin With FDA 40
Apr 25, 2011: Horizon Pharma Obtains FDA Approval For DUEXIS 40
Nov 14, 2010: POZEN Presents PA32540 Phase I Data At American Heart Association Scientific Sessions 41
Jun 09, 2010: Horizon Pharma Announces DUEXA Data To Be Presented At EULAR Annual Congress 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44



List of Tables

Number of Products under Development for Ulcers, H2 2013 7
Number of Products under Development for Ulcers - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Ulcers - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2013 15
Ulcers - Pipeline by Angelini Group, H2 2013 16
Ulcers - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2013 17
Ulcers - Pipeline by TechnoPhage SA, H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 23
Number of Products by Stage and Route of Administration, H2 2013 24
Number of Products by Stage and Molecule Type, H2 2013 26
Number of Products by Stage and Therapeutic Class, H2 2013 28
Ulcers - Dormant Projects, H2 2013 35
Ulcers - Discontinued Products, H2 2013 36



List of Figures

Number of Products under Development for Ulcers, H2 2013 7
Number of Products under Development for Ulcers - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Top 10 Target, H2 2013 20
Number of Products by Stage and Top 10 Target, H2 2013 21
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Molecule Type, H2 2013 25
Number of Products by Stage and Top 10 Molecule Type, H2 2013 26
Number of Products by Top 10 Therapeutic Class, H2 2013 27
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 28



Companies Mentioned

Ahn-Gook Pharmaceutical Co., Ltd.
Angelini Group
Laboratorios Farmaceuticos Rovi, S.A.
TechnoPhage SA

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.